title: Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids.
abstract: Inhaled and intranasal corticosteroids (ICSs) still are the most effective treatment available for allergic airway diseases and are likely to remain the cornerstone of managing persistent asthma/allergic rhinitis in the foreseeable future. Even if the therapeutic index of this class increased significantly with the introduction of newer corticosteroids, and even if new therapeutic potentials are beginning to emerge with our increasing understanding of the mechanisms of asthma, chronic obstructive pulmonary disease, and rhinitis, corticosteroid development still remains a very important field for drug designers. After a brief review of issues related to the structure-activity relationships of glucocorticoids and the main determinants of their receptor-binding affinity at the glucocorticoid receptor, the main focus of the present article will be on the development of soft corticosteroids, as they are particularly well suited to separate local activity from systemic side effects, which still is an important issue for ICSs. Design consideration required in the search for safe and effective soft drugs on one hand, and safe and effective ICSs on the other hand, will be briefly discussed and illustrated with a number of cases, in particular, with that of loteprednol etabonate and etiprednol dicloacetate, soft corticosteroids that are being developed for a full spectrum of therapeutic applications including asthma and allergic rhinitis.
authors.affiliation: IVAX Research, Inc., Miami, Florida, USA. bodor@cop.ufl.edu
authors.forename: Nicholas
authors.initials: N
authors.lastname: Bodor
authors.forename: Peter
authors.initials: P
authors.lastname: Buchwald
mesh_terms: D000305:Adrenal Cortex Hormones / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D013329:Structure-Activity Relationship
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents